Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (NCT06421675)
A Study of Elranatamab Management With Outpatient and Intermittent Dosing in Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Who can join: Review the eligibility criteria below.
Location: Vancouver Cancer Center — Vancouver, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Vancouver Cancer Center — Vancouver, British Columbia
- Juravinski Cancer Center — Hamilton, Ontario
- Kingston General Hospital — Kingston, Ontario
- London Health Science Centre - Victoria Hospital — London, Ontario
- London Health Science Centre - Victoria Hospital — London, Ontario
- Ottawa Hospital — Ottawa, Ontario
📞 Contact the Study Coordinator
Phone: (905) 527-2299
Email: aguirre@mcmaster.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Refractory Multiple Myeloma
- Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma — San Francisco, California
- Elranatamab in R/R Multiple Myeloma — Boston, Massachusetts
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma — Miami, Florida
Explore by condition: All Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.